Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of <scp>PD</scp>‐1 Inhibition as Potential Treatment Option
We report an immune phenotype consistent with T-cell exhaustion in IMI, indicating potential contributions from haematological treatment, underlying disease, and infection. However, the primary underlying cause remains unclear and requires further investigation. A marker that was notably higher in IMI patients was PD-1, and treatment approaches specifically targeting this molecule may be promising.
Authors
- Martin Thelen (ORCID: https://orcid.org/0000-0002-2785-9726)
- Michael von Bergwelt‐Baildon (ORCID: https://orcid.org/0000-0002-1952-052X)
- Leonie Marie Weskamm (ORCID: https://orcid.org/0000-0002-1175-7354)
- Jannik Stemler (ORCID: https://orcid.org/0000-0001-9152-2469)
- Leonie Mayer (ORCID: https://orcid.org/0000-0001-7102-4358)
- Marylyn M. Addo (ORCID: https://orcid.org/0000-0003-2836-9224)
- Rosanne Sprute (ORCID: https://orcid.org/0000-0003-2457-6437)
- My Linh Ly
- Christine Dahlke (ORCID: https://orcid.org/0000-0002-2056-9195)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- Hans Schlößer (ORCID: https://orcid.org/0000-0002-1304-7719)
- Monika Friedrich
- Sibylle C. Mellinghoff (ORCID: https://orcid.org/0000-0003-3928-2503)
Institutions
- Universität Hamburg (DE)
- University of Cologne (DE)
- LMU Klinikum (DE)
- Düsseldorf University Hospital (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Center for Infection Research (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ludwig-Maximilians-Universität München (DE)
- Bernhard Nocht Institute for Tropical Medicine (DE)
Publication Details
- Journal
- Mycoses
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/myc.70044
- Citations
- 3
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- Deutsches Zentrum für Infektionsforschung
- Incyte
- Bundesministerium für Bildung und Forschung
- Astellas Pharma
- Bayer Vital